166 related articles for article (PubMed ID: 34160668)
1. Lack of association between CYB5A gene rs1790834 polymorphism and the response to leflunomide in women with rheumatoid arthritis.
Łączna M; Malinowski D; Paradowska-Gorycka A; Safranow K; Dziedziejko V; Pawlik A
Eur J Clin Pharmacol; 2021 Nov; 77(11):1673-1678. PubMed ID: 34160668
[TBL] [Abstract][Full Text] [Related]
2. The association between CYB5A gene rs1790834 polymorphism and clinical improvement after 6 months of leflunomide treatment in women with rheumatoid arthritis.
Machaj F; Rosik J; Szostak B; Malinowski D; Safranow K; Olędzka G; Wiechec E; Pawlik A
Clin Rheumatol; 2023 Sep; 42(9):2477-2483. PubMed ID: 37289314
[TBL] [Abstract][Full Text] [Related]
3. CYB5A polymorphism increases androgens and reduces risk of rheumatoid arthritis in women.
Stark K; Straub RH; Rovenský J; Blažičková S; Eiselt G; Schmidt M
Arthritis Res Ther; 2015 Mar; 17(1):56. PubMed ID: 25890314
[TBL] [Abstract][Full Text] [Related]
4. Lack of association between CAG repeat polymorphism in the androgen receptor gene and the outcome of rheumatoid arthritis treatment with leflunomide.
Dziedziejko V; Kurzawski M; Safranow K; Ossowski A; Piatek J; Parafiniuk M; Chlubek D; Pawlik A
Eur J Clin Pharmacol; 2012 Apr; 68(4):371-7. PubMed ID: 21997404
[TBL] [Abstract][Full Text] [Related]
5. The effect of ESR1 and ESR2 gene polymorphisms on the outcome of rheumatoid arthritis treatment with leflunomide.
Dziedziejko V; Kurzawski M; Safranow K; Chlubek D; Pawlik A
Pharmacogenomics; 2011 Jan; 12(1):41-7. PubMed ID: 21174621
[TBL] [Abstract][Full Text] [Related]
6. [Leflunomide as a second choice treatment in patients with rheumatoid arthritis].
Raczkiewicz-Papierska A; Dudek A; Bachta A; Tłustochowicz M; Zawadyl B; Sułek M
Pol Merkur Lekarski; 2007 Jun; 22(132):547-50. PubMed ID: 17874627
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic response to leflunomide in combo therapy and monotherapy is associated to serum teriflunomide (A77 1726) levels.
Fajardo-Robledo NS; Jacobo-Cuevas H; Perez-Guerrero EE; Corona-Sanchez EG; Saldaña-Cruz AM; Romero-Tejeda EM; Rodriguez-Jimenez NA; Totsuka-Sutto SE; Lopez-Roa RI; Ponce-Guarneros JM; Alcaraz-Lopez MF; Cerpa-Cruz S; Muñoz-Valle JF; Cardona-Muñoz EG; Gonzalez-Lopez L; Gamez-Nava JI;
Sci Rep; 2022 Feb; 12(1):1877. PubMed ID: 35115601
[TBL] [Abstract][Full Text] [Related]
8. Leflunomide treatment in elderly patients with rheumatoid or psoriatic arthritis: retrospective analysis of safety and adherence to treatment.
Alivernini S; Mazzotta D; Zoli A; Ferraccioli G
Drugs Aging; 2009; 26(5):395-402. PubMed ID: 19552491
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of leflunomide in patients with active rheumatoid arthritis.
Wiacek R; Kolossa K; Jankowski T; Jeka S; Karmowski A; Karmowski M; Gworys B
Adv Clin Exp Med; 2012; 21(3):337-42. PubMed ID: 23214197
[TBL] [Abstract][Full Text] [Related]
10. The effect of exon (19C>A) dihydroorotate dehydrogenase gene polymorphism on rheumatoid arthritis treatment with leflunomide.
Pawlik A; Herczynska M; Kurzawski M; Safranow K; Dziedziejko V; Drozdzik M
Pharmacogenomics; 2009 Feb; 10(2):303-9. PubMed ID: 19207032
[TBL] [Abstract][Full Text] [Related]
11. Quality of life and clinical outcomes in Polish patients with high activity rheumatoid arthritis treated with leflunomide (Arava®) in Therapeutic Program: A retrospective analysis of data from the PLUS study.
Tłustochowicz ME; Kisiel B; Tłustochowicz W
Adv Clin Exp Med; 2019 Nov; 28(11):1545-1553. PubMed ID: 31660707
[TBL] [Abstract][Full Text] [Related]
12. Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide (A77 1726) pharmacokinetics in leflunomide-treated patients with rheumatoid arthritis.
Bohanec Grabar P; Grabnar I; Rozman B; Logar D; Tomsic M; Suput D; Trdan T; Peterlin Masic L; Mrhar A; Dolzan V
Drug Metab Dispos; 2009 Oct; 37(10):2061-8. PubMed ID: 19581389
[TBL] [Abstract][Full Text] [Related]
13. Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients.
Bohanec Grabar P; Rozman B; Tomsic M; Suput D; Logar D; Dolzan V
Eur J Clin Pharmacol; 2008 Sep; 64(9):871-6. PubMed ID: 18496682
[TBL] [Abstract][Full Text] [Related]
14. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group.
Strand V; Cohen S; Schiff M; Weaver A; Fleischmann R; Cannon G; Fox R; Moreland L; Olsen N; Furst D; Caldwell J; Kaine J; Sharp J; Hurley F; Loew-Friedrich I
Arch Intern Med; 1999 Nov; 159(21):2542-50. PubMed ID: 10573044
[TBL] [Abstract][Full Text] [Related]
15. Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritis.
Wiese MD; Schnabl M; O'Doherty C; Spargo LD; Sorich MJ; Cleland LG; Proudman SM
Arthritis Res Ther; 2012 Jul; 14(4):R163. PubMed ID: 22784880
[TBL] [Abstract][Full Text] [Related]
16. The effect of leflunomide on the eye dryness in secondary Sjögren's syndrome associated with rheumatoid arthritis and in rheumatoid arthritis patients.
Shahin AA; El-Agha S; El-Azkalany GS
Clin Rheumatol; 2014 Jul; 33(7):925-30. PubMed ID: 24647977
[TBL] [Abstract][Full Text] [Related]
17. Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort.
Lukas C; Mary J; Debandt M; Daïen C; Morel J; Cantagrel A; Fautrel B; Combe B
Arthritis Res Ther; 2019 Nov; 21(1):243. PubMed ID: 31730497
[TBL] [Abstract][Full Text] [Related]
18. Clinical deep remission and related factors in a large cohort of patients with rheumatoid arthritis.
Liu JJ; Li R; Gan YZ; Zhang RJ; Li J; Cai YM; Zhao JX; Liao H; Xu J; Shi LJ; Li J; Li SG; Sun XL; He J; Liu X; Ye H; Li ZG
Chin Med J (Engl); 2019 May; 132(9):1009-1014. PubMed ID: 30946065
[TBL] [Abstract][Full Text] [Related]
19. Systematic review and meta-analysis of the efficacy and safety of leflunomide and methotrexate in the treatment of rheumatoid arthritis.
Alfaro-Lara R; Espinosa-Ortega HF; Arce-Salinas CA;
Reumatol Clin (Engl Ed); 2019; 15(3):133-139. PubMed ID: 28867467
[TBL] [Abstract][Full Text] [Related]
20. Precision Medicine With Leflunomide: Consideration of the DHODH Haplotype and Plasma Teriflunomide Concentration and Modification of Outcomes in Patients With Rheumatoid Arthritis.
Wiese MD; Hopkins AM; King C; Wechalekar MD; Lee A; Spargo L; Metcalf R; McWilliams L; Hill C; Cleland LG; Proudman SM
Arthritis Care Res (Hoboken); 2021 Jul; 73(7):983-989. PubMed ID: 32339392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
